Equities

agilon health inc

AGL:NYQ

agilon health inc

Actions
Health CareHealth Care Providers
  • Price (USD)1.81
  • Today's Change0.03 / 1.69%
  • Shares traded913.23k
  • 1 Year change-84.70%
  • Beta0.5012
Data delayed at least 15 minutes, as of Nov 22 2024 17:41 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year agilon health inc had net income fall 146.45% from a loss of 106.55m to a larger loss of 262.60m despite a 80.74% increase in revenues from 2.39bn to 4.32bn. An increase in the cost of goods sold as a percentage of sales from 87.67% to 92.87% was a component in the falling net income despite rising revenues.
Gross margin2.00%
Net profit margin-5.73%
Operating margin-6.42%
Return on assets-14.04%
Return on equity-42.40%
Return on investment-36.97%
More ▼

Cash flow in USDView more

In 2023, cash reserves at agilon health inc fell by 393.35m. Cash Flow from Investing was negative at 44.02m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 156.20m for operations while cash used for financing totalled 193.13m.
Cash flow per share-0.7023
Price/Cash flow per share--
Book value per share1.40
Tangible book value per share1.16
More ▼

Balance sheet in USDView more

agilon health inc has a Debt to Total Capital ratio of 5.72%, a higher figure than the previous year's 3.99%.
Current ratio1.29
Quick ratio--
Total debt/total equity0.0607
Total debt/total capital0.0572
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.